Introduction
============

Aging causes an increasing susceptibility to cognitive performances due to a developing neurodegeneration leading to neurologic disorders, such as dementia. More than 20 million people worldwide suffer from dementia, and this number is expected to exceed 80 million by 2040 because of the rapid increase in the numbers of the elderly [@B1]. Alzheimer's Disease (AD) is an irreversible progressive neurodegenerative disease affecting the central nervous system. Despite the increasing rate of AD incidence, no therapeutic strategy has been developed yet [@B2]. Pathophysiologically, AD-related brain severe shrinkage caused neural and synaptic degenerations [@B3]. The mentioned degenerative events can be detected in post mortem examination of patients suffering from severe memory loss [@B4],[@B5]. It is thought that the loss of memory is because of aggregating beta amyloid (Aβ) and Neurofibrillary Tangles (NFTs) of hyper-phosphorylated tau protein [@B1],[@B6]. Additionally, inflammation characterized by activated microglia [@B7] and oxidative stress, which result from an imbalance of Reactive Oxygen Species (ROS) and antioxidants [@B8],[@B9] were shown to be associated with AD. Epigenetic changes happening in pre-frontal region by aging were shown to be related with AD functioning at cognitive level [@B1].

Rewiring of the biological networks to detect co-regulated and co-expressed units will help to facilitate looking into network's components and depicting the relationships between interconnected genes. Gene co-expression networks enable us to highlight molecular mechanisms underlying diseases [@B10] and are considered as one way to investigate the etiology of AD efficiently. A large number of co-expression network methods have been proposed in the literature [@B11],[@B12]. Differential Co-expression Analysis (DCEA) offers a powerful approach for exploring phenotypic changes [@B13]. Not only is AD etiology incompletely understood but also differences at transcriptome level and the genes potentially related to each distinct regions of brain are not recognized causing AD to be remained somewhat unclear. In the present study, a high-throughput genomic screening approach was applied using DCGL software and comparative microarray analyses. It was hypothesized that the distinct transcriptional changes in different regions of brain lead to AD-associated brain damages. Therefore, the transcriptional profiles from the gray matter of frontal and temporal cortices were compared with hippocampi derived postmortem brains to dissect AD pathogenesis in these areas. The rationale behind the used network approach is to prioritize AD-causative genes that are apart from differential alterations in their expression and are differentially regulated by Transcription Factors (TFs) between contrasting samples. For this, Differential Regulation Analysis (DRA) has been conducted on three separated regions of AD brains as contrasting samples.

Materials and Methods
=====================

Data acquisition and pre-processing
-----------------------------------

The *CEL* *files* for GSE36980 series were downloaded from the GEO (<http://www.ncbi.nlm.nih.gov/geo/>) database and normalized with RMA method by using the Linear Models for Microarray Data (limma) R package. The main reason for selecting and exploiting this dataset is that GSE36980 series cover interspecies transcriptome analysis of various regions in gray matter in postmortem brains suiting the goal of dissecting pathological alterations in AD in several brain areas. Moreover, a number of researches have previously used these series and therefore would be able to compare the findings. After removing ambiguous probes, the extracted probe IDs were transformed into gene symbols. This data consists of a total of 79 samples ([Table 1](#T1){ref-type="table"}) based on the platform of GPL6244 and correspond to the frontal and temporal cortices and hippocampus.

###### 

Sample characteristics

  **Biological samples**   **Control**   **AD patients**
  ------------------------ ------------- -----------------
  Temporal cortex          19            10
  Frontal cortex           18            15
  Hippocampus              10            7

Network construction
--------------------

The DCGL R package was used to conduct DCEA [@B13],[@B14]. This software firstly calculates Differential Co-expression profile (DCp) and Differential Co-expression enrichment (DCe) to extract significant co-expression changes between a pair of genes in control and treatment samples. Next, Differentially Co-expressed Genes (DCGs) and Differentially Co-expressed Links (DCLs) were summarized from DCp and DCe values.

Next, DCGs and DCLs were extracted from DCp and DCe values previously calculated by DCp and DCe functions. DCp filters co-expression values of a pair of genes were assessed in control and treatment conditions. *X* and *Y* were defined as a subset of the gene pairs, where *n* is co-expression neighbors for a gene; *X =* (x~i~1, x~i~2, ..., x~i~n)*Y =* (y~i~1, y~i~2, ..., y~i~n)

The DC of a given gene is calculated with the following equation: $$\mathit{DC}_{n}(i) = \sqrt{\frac{\left( {x_{i1} - y_{i1}} \right)^{2} + \left( {x_{i2} - y_{i2}} \right)^{2} + \ldots + \left( {x_{in} - y_{in}} \right)^{2}}{n}}$$

If the resulting DCGs and DCLs coincide with a TF, they will be referred to as a DRG and DRL, respectively. The DRGs and DRLs were scrutinized by DR-sort function in Differential Regulation Analysis (DRA) module. In fact, DRA module identifies potential TF as upstream regulators of DCGs and DCLs [@B13]. Finally, for illustrating the interactions between DRGs and their regulators, a network of DRGs and coincided TFs obtained by DRA was built for each of the datasets. By utilizing the Network Analyzer [@B15] nodes were set within networks with higher connections to darker color and bigger size.

Gene ontology, pathway analysis and visualization
-------------------------------------------------

To find the significantly over-represented biological GO terms and functions of gene products within a co-expression network of DRGs and DRLs, functional classification was performed using BINGO Cytoscape plugin [@B16] running hypergeometric test and Benjamini & Hochberg FDR correction at significant level 0.01. Finally, the clusters were visualized by Enrichment map Cytoscape plugin with Jaccard's coefficient 0.001. DRGs were further functionally classified by PANTHER database (<http://pantherdb.org/>) to underlying pathways ([Figure 1](#F1){ref-type="fig"}).

![Bar chart of pathways potentially DRGs extracted from tempral cortex, frontal cortex and hippocampus expression data. PANTHER server with default parameters for pathway analysis was used for pathway analysis. The length of each bar showes how many genes have been assigned to a given pathway.](AJMB-10-233-g001){#F1}

Results
=======

Co-expression analysis
----------------------

The expression values of GSE36980 datasets were analyzed by utilizing DCGL v2.0 R package with default parameters. A total of 17088 unique genes were subjected to expression based filter and variance based filter, two functions embedded in DCGL to filter out genes that expressed extreme invariability across control and AD samples yielding 8544 and 2918 genes, respectively (Supplementary file 1). Afterward, using 2918 unique genes, co-expression analysis was performed on temporal cortex, frontal cortex, and hippocampus datasets separately. Expression based filter removes genes whose mean expression between experiments is lower than the median of this value for all genes and variance based filter removes genes that are not significantly variable than the median gene [@B13]. In order to prioritize seed genes which are potentially related to AD pathogenesis, common and significant DRGs were selected using Targets' Enrichment Density (TED) analysis and Targets' DCL Density (TDD) analysis. TED and TDD identify differential co-expression genes and link in a particular TF's targets, respectively [@B13]. To this end, targets of significant TFs were extracted from 19,9950 TF-to-target interaction pairs as a library in DCGL v2.0 software [@B13]. These pairs were further filtered out based on DRLs. In sum, 7, 19 and 13 genes were identified in temporal cortex, frontal cortex and hippocampus, respectively ([Table 2](#T2){ref-type="table"}). Significant TFs derived by TED and TDD analysis were used to infer co-expression network of DRGs in each dataset independently ([Figure 2](#F2){ref-type="fig"}, Supplementary figures). DRGs were classified in terms of response to lipid, response to fatty acid, regulation of transcription from RNA polymerase II promoters and regulation of nitrogen compound metabolic process ([Figure 3](#F3){ref-type="fig"}). Moreover, in pathway analysis, signaling pathways such as glutamate and G-protein signaling pathways were noteworthy ([Figure 1](#F1){ref-type="fig"}).

![Differential co-expressed network of DRGs and DRLs captured by TED and TDD results in temporal cortex datasets. The bigger and darker nodes show the nodes with higher connectivity within the network.](AJMB-10-233-g002){#F2}

![Functional classification of biological process in which Differential Regulated Genes (DRGs) were supposed to be involved. The GO terms were considered significant based on hypergeometric test with Benjamini & Hochberg FDR correction and significance level 0.01 by BINGO app. The results were illustrated using the Enrichment map Cytoscape 3.4.0 plugin. Ticker lines and bigger circles show more genes with higher significance level belonging to a given term.](AJMB-10-233-g003){#F3}

###### 

List of differential regulated genes (DRGs) and corresponding p-value\<0.05 of differential co-expression enrichment (DCe) in temporal cortex, frontal cortex and hippocampus datasets

                        **Gene name**   **DCe p-value**                                                                                                                                                               **Description**
  --------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  **Temporal cortex**   *ARID1A*        0.00069                                                                                                                                                                       *ARID1A* was among down-regulated genes in AD model mice ([@B17])
  *Cdc42*               0.01224         *Cdc42* activity was increased in hippocampus neurons treated with fibrillary β-amyloid ([@B18])                                                                              
  *LPPR4*               0.01395         LPPR4 was up-regulated in incipient AD patients ([@B19])                                                                                                                      
  *PITHD1*              0.01863         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *SGIP1*               0.02064         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *SZT2*                0.01936         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *ZMPSTE24*            0.01936         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
                                                                                                                                                                                                                      
  **Frontal cortex**    *CHD5*          5.19E-14                                                                                                                                                                      The depletion of *CHD5* was shown to be linked with AD associated gene sets ([@B20])
  *EFHD2*               3.00E-07        *EFhd2* has been found to be associated with aggregated tau in the brain in AD and in a mouse model of frontotemporal dementia ([@B21],[@B22])                                
  *Prxs*                7.82E-07        Peroxiredoxins (Prxs) may be associated with AD by reducing ROS elicited by amyloid β (Aβ) accumulation that could be a causative factor in the pathogenesis of AD ([@B23])   
  *MAGIE3*              1.68E-06        [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *EXTL1*               4.14E-06        [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *HPCAL4*              2.09E-05        *HPCAL4* could be used as a prognostic marker for cognitive decline in AD ([@B24])                                                                                            
  *LPHN2*               2.59E-05        *LPHN2* is likely to be participated in AD as an altered protein in Lipid Raft ([@B25])                                                                                       
  *NIPAL3*              8.35E-05        *NIPAL3* was shown as a biomarker in Late-Onset Major Depressive Disorder ([@B26])                                                                                            
  *CACNA1E*             0.00017         *CACNA1E* was down-regulated in cerebral Cockayne syndrome ([@B27])                                                                                                           
  *IFI16*               0.00033         IFI16 was participated in delaying onset of AD ([@B28])                                                                                                                       
  *HHLA3*               0.00122         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *KCNK1*               0.00202         *KCNK1* exhibited alternative splicing in patients with mesial temporal lobe epilepsy ([@B29])                                                                                
  *rnpc3*               0.00384         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *DCAF6*               0.00542         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *IPO13*               0.00581         *IPO13* mutants involved in chronic inflammatory diseases ([@B30])                                                                                                            
  *RPL11*               0.00585         *RPL11* revealed significant altered expression profiles in the neuron model of AD treated with rhTFAM ([@B31])                                                               
  *S100A1*              0.00716         *S100A1* modulates inflammation in AD ([@B32])                                                                                                                                
  *CNTN2*               0.02606         *CNTN2* associated with AD via *BACE1* activity ([@B33])                                                                                                                      
  *GRIK3*               0.03774         *GRIK3* was highly expressed in major depression ([@B34])                                                                                                                     
                                                                                                                                                                                                                      
  **Hippocampus**       *KCNK1*         1.55E-09                                                                                                                                                                      [//](#TFN1){ref-type="table-fn"}
  *CHRNB2*              2.37E-09        *CHRNB2* was found to interfere with the immune system in neurologic disorders ([@B35])                                                                                       
  *HAPLN2*              3.43E-05        *Hapln2* has been recently shown to be accumulated in the neurofibrillary tangle of Alzheimer's brain ([@B36])                                                                
  **Slc2a1**            0.00207         **Slc2a1* down-regulation exacerbated AD ([@B37])*                                                                                                                            
  *FABP3*               0.00298         serum levels of brain-type *FABP* are elevated in a significant proportion of patients with various neurodegenerative diseases including AD ([@B38])                          
  *DEGS1*               0.00327         *DEGS1* is likely to be involved in AD as an altered protein in Lipid Raft ([@B25])                                                                                           
  *NKAIN1*              0.00435         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *S100A1*              0.00434         *S100A1* modulates inflammation in AD ([@B32])                                                                                                                                
  *CNTN2*               0.00511         *CNTN2* associated with AD via b-Secretase (*BACE1*) activity ([@B33])                                                                                                        
  *SFPQ*                0.00816         *SFPQ* was shown as a transcription factor with an altered nucleo-cytoplasmic distribution under neurodegenerative conditions ([@B39])                                        
  *GPSM2*               0.01073         [//](#TFN1){ref-type="table-fn"}                                                                                                                                              
  *GSTM1*               0.01591         *GSTM1* null genotype was found as risk factor for late-onset Alzheimer's disease in Italian patients ([@B40])                                                                
  *CACHD1*              0.02830         *CACHD1* is a substrate of *BACE1* responsible for generating the amyloid-b protein ([@B41])                                                                                  

showing DRGs with ambiguous role in neurologic disorders.

Temporal cortex
---------------

460 DCGs and 33656 DCLs were summarized using DC sum function to a final set of DCGs and DCLs (Supplementary file 2). There were 199 significant TFs in the results of TED analysis and 35 significant TFs in TDD analysis. 35 TFs that were significant in both of these two analysis results were chosen (Supplementary file 2). DRA analysis yielded 7 DRGs and 33 DRLs. DRGs were not only differentially co-expressed but also differentially co-regulated with 35 mentioned TFs. Then, a network of DRGs and DRLs was visualized using Cytoscape 3.4.0. Based on [figure 2](#F2){ref-type="fig"}, *PAX5* transcription factor and genes including *ARID1A*, *CDC42* and LPPR4 were highlighted as the most important units within the genes network with more interconnected links ([Figure 2](#F2){ref-type="fig"}).

Frontal cortex
--------------

In frontal cortex datasets, 628 DCGs and 166256 DCLs were summarized to 20 DRGs and 164 DRLs (Supplementary file 3). There were 199 significant TFs in TED analysis result and 135 significant TFs in TDD analysis result from which 135 TFs were chosen that were significant in both TED and TDD results (Supplementary file 3). In the inferred network, *PAX5* and *IKZF1* as TFs and genes including *GRIK3*, *MAGI3*, *PRRX1* and *DCAF6* were found as highlighted nodes with more connectivity.

Hippocampus
-----------

According to hippocampus datasets, 670 DCGs and 56264 DCLs were summarized to 16 DRGs and 43 DRLs (Supplementary file 4). There were 199 common and significant TFs in TED and TDD analysis which were used for inferring differential co-expression network with DRGs. There was more connectivity in hippocampus network than the other two networks. *PAX5*, *ARNT*, *GATA1*, *EGR3* and *IKZF1* TFs and genes including *KCNK1*, *CACHD1*, *FABP3* and *CHRNB2* showed highlighted roles as network nodes.

Discussion
==========

Aging is believed to be one of the most important non-modifiable risk factors of cognitive diseases that lead unequivocally to a number of detrimental changes in the neural system, increasing neuromorbidity and mortality. AD, as a progressive neurodegenerative disorder with no effective treatment options, is typically characterized by the presence of amyloid-beta plaques and hyper phosphorylated paired helical filament tau protein-rich neurofibrillary tangles [@B1]. The identification of co-expressed genes related to AD presumably provides insights into the underlying mechanisms; in other words, a combination of gene effects likely holds promise as a more effective approach for detecting disease associated genes [@B42]. In fact, examining co-expressed genes in spite of the individual genes could be more informative to explore genes that cause mental health disorders, such as AD [@B43],[@B44]. In this case, the correlation between two genes varies in distinct samples and thereby they are referred to as being differentially co-expressed. This correlation may change independently from the expression levels of two genes, indicating that transcriptome analysis merely based on differential expression analysis could miss important clues of regulatory patterns [@B45]. Co-expression analysis has been performed for deciphering molecular mechanisms underlying mental health disorders [@B46]--[@B49]. In the context of a well-established network analysis approach and given the most variable transcripts between control and AD brain samples, attempts were made by DCGL framework to explore putative pivotal genes that may be associated with AD. This work attempted to identify DRGs and links DRLs in AD by comparing expression datasets of temporal and frontal cortices and hippocampi. A comprehensive search in the literature showed that the obtained DRGs of AD brains mostly have direct or in-direct links with AD or another neurologic disorder ([Table 2](#T2){ref-type="table"}). They are implicated in the gene ontology terms and shared biological pathways like response to lipid, fatty acid, nitrogen compound metabolic process and glutamate signaling pathways ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, supplementary file 5). Reportedly, considering GO terms as the response to lipid and fatty acid, brain lipid homeostasis plays an important role in AD [@B50]. In this regard, differential regulation of delta 4-desaturase, sphingolipid 1 (*DEGS1*) and fatty acid binding protein 3 (*FABP3*) in hippocampus and lipid phosphate phosphatase-related protein type 4 (*LPPR4*) in temporal cortex datasets may fairly explain the relationship between brain damages happening in these regions and lipid metabolism. *DEGS1* encodes a member of the membrane fatty acid desaturase family which is shown to interfere in AD via lipid rafts [@B25]. FABP proteins are thought to participate in the uptake, intracellular metabolism and/or transport of long-chain fatty acids. Concordantly, serum levels of brain-type *FABP* are elevated in a significant proportion of patients with various neurodegenerative diseases including AD [@B38]. *LPPR4* acts as phospholipid dephosphorylate involving axonogenesis. The control of ion flow across the lipid membrane is essential for many cellular functions, including neuronal excitability and dysfunction of conveying ions through lipid bilayers involved in multiple neurologic diseases [@B51]. As illustrated in [figure 1](#F1){ref-type="fig"}, the DRGs are more implicated in signaling pathways; but the DRGs from frontal cortex were more enriched in ionotropic glutamate receptor pathway and metabo-tropic glutamate receptor group II and III pathways. The dysregulation of glutamatergic signaling has been shown to be associated with AD. Glutamate acts *via* ionotropic glutamate receptors (*iGluR*) and metabo-tropic glutamate receptors (*mGluR*), both of which have been implicated in AD [@B52]. Differential regulation of glutamate receptor ionotropic, kainate 3 (*GRIK3*) and voltage-dependent R-type calcium channel subunit alpha-1E (*CACNA1E*) in frontal cortex datasets may be biologically relevant with the mentioned pathways in AD brain areas. Concordantly, a significant change in the expression of the *GRIK3* gene was detected in a patient diagnosed with severe developmental delay [@B53]. Many different kinds of signaling pathways are changed in AD, indeed the relevance of the biological pathways shown in [figure 1](#F1){ref-type="fig"} such as cytoskeletal regulation by Rho GTPase suggests mediating of these signaling pathways in the different lobs of brain, in this case in temporal cortex with differential regulation of *CDC42*. *CDC42* has been linked to neuronal diseases like Alzheimer and Parkinson's disease through its role in cytoskeletal organization [@B54]. Among the DGRs, *CNTN2*, *KCNK1* and *S100A1* were found common in frontal cortex and hippocampus datasets. S100A1 encodes for calmodulin signaling molecules. Increased levels of calmodulin have been reported in the hippocampus of AD model mice [@B55]. These changes seemingly show an aberrant involvement of calmodulin in the impairment of cell cycle control in AD. As for the potassium channel subfamily K member 1- *KCNK1*, recent genetic studies suggest a central role for neuroinflammation. *KCNK1* is a voltage-gated potassium channel upregulated by activated microglia and a mediator in amyloid-mediated microglial priming, additionally reactive oxygen species production that was shown to be related with autoimmunity [@B56]. CNTN2 has been shown to undergo nuclear translocation and altered transcription [@B33].

These findings probably show that hippocampus and frontal cortices might deeply play a role in AD by mediating with conveying ions. Their obtained DRGs participated in vital processes like signaling, ion transportation and homeostasis. However, these processes mostly signal pathways somehow shared with temporal cortex implying the role of signal molecules within and between brain areas in neurologic dysfunctions. Concordantly, a comprehensive study has been already carried out on GSE36980 series to examine the alteration in the expression of diabetes-related genes in AD brains where they illustrated that hippocampi of AD brains have the most significant alteration in gene expression profile [@B57].

With a glance at [table 2](#T2){ref-type="table"} and the terms including amyloids, inflammation, ROS and immune system, one could infer a cascade of events in which the DRGs interfere. Beta-amyloid deposition following the activation of microglia will initiate an inflammatory response leading to the release of potentially neurotoxic substances and ROS that targets neural damage [@B58]. Afterward, along with immune response, nitrogen compounds will mediate to reverse the consequences of oxidative stress in damaged regions [@B8],[@B9]. In sum, it was shown that DRGs covered a wide range of known functions and processes implicated in main AD signaling pathways. In a study by Satoh *et al* [@B59], GSE36980 series used in the present study were utilized to identify biomarker genes relevant to the molecular pathogenesis of AD. They analyzed a RNA-Seq dataset composed of the transcriptome of postmortem AD brains derived from two independent cohorts and they identified the core set of 522 genes deregulated in AD brains shared between both, compared with normal control subjects. Notably, in agreement with our study, LPPR4 was bolded in AD brains in both microarray and RNA-seq datasets. By consistent downregulation of NeuroD6 in AD brains, the results indicated that downregulation of NeuroD6 serves as a possible biomarker for AD brains. Previous studies identified LPPR4 as direct target genes for NeuroD6 by binding assay to E-boxes located in target gene promoters [@B60]. GSE36980 series were also employed by Fowler *et al* [@B61] used to investigate potential underlying biology in AD and in concordance with the results of the present study, they noticed the overrepresentation of glutamate in their data mining. They first identified genes consistently associated with AD in each of the four separate expression studies, and confirmed the result using a fifth study. They next developed algorithms to search hundreds of thousands of GEO data sets, identifying a link between an AD-associated gene (NEUROD6) and gender. Additionally, they identified several genes related to glutamate (including CACNG3, a regulator of AMPA-sensitive glutamate receptors; SLC17A7, a mitochondrial oxoglutarate carrier; and GOT2, mitochondrial glutamic-oxaloacetic transaminase. In our study, differential regulation of glutamate receptor ionotropic, kainate 3 (GRIK3) and voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E) in frontal cortex datasets could be therefore biologically relevant with the mentioned pathways in AD brain areas. Moreover, in our study, differential regulation of Slc2a1 in hippocampus data seemingly implies the role of impairments in glutamatergic transmission mostly in hippocampus of AD brains. The role of glutamate transporters such as SLC1A6 was also highlighted in a study by Satoh *et al* [@B59].

Conclusion
==========

The purpose of the study was to explore the molecular mechanism in the development of AD, and a comparison of AD in three regions of the brain was done. Therefore, in the frame of network reconstruction and data mining approaches, a small number of possible genes and TFs were identified that their interplay could lead to neural dysfunctions toward AD. However, one should be cautious regarding small sample size while by utilizing more adequate samples, the results would be more reliable evidences.

An expected outcome of such a work would possibly shed light on the bridges between AD-associated brain damage in transcriptome level and presenting crucial evidence in clinical diagnosis and treatment.
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